Leading Antipsychotic Drugs Come Under New Scrutiny – NYT Tuesday, May 20, 2003 A front page article in The New York Times reveals that the pillars of American psychiatry–including Dr. Jeffrey Lieberman, Dr. John Kane, Dr. William Carpenter–are acknowledging that evidence is lacking to support the claims that the new…
How Genentech, Novartis Stifled A Promising Drug – WSJ Tue, 05 Apr 2005 A front page story in The Wall Street Journal should be distributed to every Congress person who will be considering Bioshield II providing yet additional financial incentives and give-a-ways to pharmaceutical companies. The story perfectly illustrates this…
Doctors Without Borders: Why you can’t trust medical journals anymore Tue, 13 Apr 2004 Related link: Hear an interview with Shannon Brownlee on NPR at: http://www.npr.org/features/feature.php?wfId=1874563 Doctors Without Borders in the Washington Monthly (excerpt below), looks at the intricate web of collaborating players in medicine who are financially tied one…
Drugmakers Go Furthest to Sway Congress: 1,274 Lobbyists – USA Today Tue, 26 Apr 2005 USA Today provides a glimpse into the way the pharmaceutical industry controls health care policy by buying influence at the highest level of government, and underwriting professional and lay healthcare organizations whose spokespersons parrot industry’s…
Leading ADHD Researcher Blows Whistle on Concerta & CHADD Fri, 3 Dec 2004 A newly released report by the Center for Disease Control – Health US 2004–reveals how effective the pharmaceutical industry is in marketing its drugs – whether or not they are beneficial; whether or not they cause severe…
Antipsychotic Drug Use Doubled since 1996 in Tennessee Children – Why? Thu, 2 Sep 2004 A Vanderbilt University study found that the use of antipsychotic drugs has doubled among poor children in Tennessee. “The increase, seen largely among children diagnosed with attention-deficit/hyperactivity disorder (ADHD), conduct disorder and affective disorders such…
The risks of the drugs far outweigh their benefits, said Vera Sharav, president of the Alliance for Human Research Protection, a New York-based consumer advocacy group.
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
An editorial in today's New York Times is a follow-up to its riveting report by Ian Urbina on the recommendation by an Institute of Medicine panel to
lift 1978 federal restrictions on medical experiments on prisoners. http://www.nytimes.com/2006/08/13/us/13inmates.html?
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
